Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
Solid-tumor CAR-T overcomes antigen heterogeneity and hostile TME through armored designs, logic gates, and regional delivery; satri-cel's world-first approval marks a pivotal 2026 milestone.
In vivo CAR-T delivers genetic instructions directly to patients, eliminating ex vivo manufacturing; lentiviral platforms lead clinically, with $5.9B in pharma acquisitions validating the modality.
PSMA radioligand therapy anchors prostate cancer theranostics, expanding earlier via VISION/PSMAfore, with alpha emitters, antibody conjugates, and pipeline competition driving the 2026 landscape.
PSMA-SSTR RLT anchors precision oncology; alpha emitters, earlier-line trials, and pan-tumor targets drive the next theranostic decade.
Radiopharmaceuticals consolidate as precision oncology pillar: PSMA/SSTR targeting, alpha-particle platforms, and scaled manufacturing drive the $10B+ field toward 2030.
ADC resistance spans antigen loss, trafficking defects, efflux, target mutations, and microenvironment barriers; payload-class switching and quantitative biomarkers guide counterstrategies.
B7-H3 ADCs near first approval, with TOP1i payloads leading; safety differentiation and China-driven innovation define the competitive landscape.
T-DXd anchors the HER2 ADC landscape while next-generation agents differentiate on tolerability, payload class, and biomarker-driven sequencing.
Three TROP2 ADCs now anchor breast cancer care, with safety profiles dictating agent selection while China drives next-generation pipeline expansion.
Next-generation ADCs redefine oncology through site-specific conjugation, payload diversification, expanding targets, and toxicity management expertise.
Oncology asset valuation hinges on clinical phase, biomarker precision, and trial data quality—deal structures mirror this risk hierarchy.
Oncology M&A hits $22B in 2025, driven by ADCs, bispecifics, and in vivo cell therapy platforms.
China biotech out-licensing surged to $137.7B in 2025, driven by ADCs, bispecific antibodies, and portfolio-level pharma collaborations.
Oncology licensing surged through 2026, driven by milestone-heavy deals, China's rise, and ADC/bispecific dominance.
In vivo CAR-T cell therapy is advancing from preclinical proof-of-concept into early clinical trials, attracting major pharma investment.
In vivo CAR-T could reshape cell therapy by eliminating ex vivo manufacturing — promising faster, cheaper treatment, though clinical validation remains early.
In vivo CAR-T review: 10 issues remain unfixed, 2 new findings—"semi-in-vivo" and Descartes-08 SLE overstatement persist.
In vivo CAR-T has entered early clinical validation, with $15B+ in deals, but regulatory and durability questions remain through 2029.
In vivo CAR-T enters clinical validation as pharma bets billions on lentiviral and LNP platforms.
Autoimmune biotech deals surge in volume, but milestone-heavy structures and biomarker-driven differentiation define the new selectivity.